Reversing Aging: Screening, Wearables & What To Do Now

Young aligns his framework with the host's (Kara Fitzgerald) approach, emphasizing that these basics form the 'longevity bridge' that works today. He breaks it down: diet, exercise, sleep and mental peace (including meditation, sense of purpose, acts of kindness), annual comprehensive medical screening, and conscious risk-taking choices (like wearing seat belts, not smoking, avoiding extreme sports with high mortality). He adds that people must become the 'director of the orchestra of their own health' rather than delegating all decisions to pharma, insurers, and food companies. This framework is anchored in data he cites: smoking costs 10 years of lifespan; not wearing a seatbelt costs 2 years; motorcycles are 17 times more lethal than cars; climbing K2 has a 25% mortality, Annapurna 33%, making them comparable to Russian roulette with two bullets. He highlights that these are controllable choices that dramatically shift longevity.

Young's fervor for medical screening is the heart of his health advice. He shares that he tells everyone the most important day of the year is not their birthday but the day of their medical screening. He recounts multiple stories of friends and colleagues whose lives were saved by early detection—cancer found at stage 1, treated with full recovery, no loss of quality of life. He contrasts the current fragmented, reactive healthcare system (6-month feedback loops) with what is possible using modern screening tools: whole-body MRI that detects cancer in 99% of cases, blood-based AI-powered multi-cancer tests detecting up to seven cancer types for a couple hundred dollars. He has personally used Fountain Life's advanced screening (including a two-based test that is switching to blood) for the past three years. He believes combining these technologies with annual discipline will render age-related cancer a manageable condition, much like heart disease is today.

Young describes his CGM practice as a transformative feedback tool. Every three months, he wears a CGM for two weeks, and the data directly informs his food choices. He shares two vivid personal examples: 1) Every time he sees gelato in Italy, he now mentally pictures the CGM trace spiking if he eats it on an empty stomach, which deters him. 2) He used to love freshly squeezed orange juice but discovered it was a 'sugar bomb' for his blood sugar. This immediate feedback loop—glucose data within minutes—creates a Pavlovian association that persists long after the sensor is removed. He argues that this kind of feedback, previously unavailable outside a lab, is now democratized and can help anyone fine-tune their diet for metabolic health. He contrasts this with the old model of getting a fasting glucose once every six months at the doctor, which provides almost no behavioral insight.

Young is a zealous wearable user. He credits the Oura ring with providing sleep metrics without a screen, which would disturb his rest. During the day, his Apple Watch (or any smartwatch) prompts him to close activity rings, a feature he says studies show adds 30-40% to physical activity levels. He personally chases the 10,000-step goal, sometimes walking around his apartment at 10:30 PM to hit the number before midnight, even though he knows statistically the longevity benefit plateaus after about 5,500-6,000 steps. This gamification, he argues, is a powerful behavioral nudge. He acknowledges the market is tough for new wearable startups due to giants like Apple and Garmin, but the consumer benefit is already enormous.

Young briefly mentions he is wearing an Apollo Neuro device (which he pronounces 'polonure apollonure'). It stimulates the nervous system through mild vibration, and he uses it to help increase his HRV. He places this in the context of the expanding wearables ecosystem—devices that go beyond mere tracking to active intervention. While he does not elaborate on protocol details or outcomes, his endorsement signals that stress management via biofeedback wearables is part of his personal longevity stack. The mention aligns with his broader thesis that continuous physiological data and targeted stimulation will close the feedback loop and improve health.

Young frames risk avoidance as the fifth pillar of his framework. He provides stark statistics to jolt the audience: tobacco smoking costs a decade of life; not buckling up costs two years; riding a motorcycle is 17 times more lethal than driving a car. He then highlights voluntary extreme sports—his friend summiting K2 (25% mortality) and Annapurna (33%)—and compares it to playing Russian roulette with two bullets. His point: we often delegate health choices to systems, but we also have agency over risks we take. He wants people to calculate the 'risk-return choices' in their lives. This is not about eliminating joy, but about recognizing that many lethal risks are optional and that 'it's always going to happen with someone else' is a fallacy.

Young argues that as lifespan and healthspan extend, the linear life path—education, work, retirement—will dissolve. Instead, people will experience multiple distinct 'mini-lives' of 10-20 years each, where they can start new families with different partners, switch careers entirely, and reinvent themselves. This is not a judgment of good or bad, he says, but an evolutionary inevitability driven by the quantity of extra years triggering a qualitative change in the life cycle. He contrasts this with his personal stance: he is not a fan of immortality and believes removing death would fundamentally alter what it means to be human. Rather than focusing on a binary immortality choice, the future will offer periodic decisions—every 5-10 years—about whether to extend one's lifespan, making longevity a conscious, ongoing selection.

Young distinguishes between the fantasy of immortality and the realistic trajectory of healthspan science. He predicts that advances will not suddenly grant eternal life but will allow individuals to periodically decide to extend their remaining healthy years. This model normalizes aging interventions as a choice—like a subscription—potentially making it less terrifying and more democratized. He notes that this decision-making will emerge naturally as treatments become available, and society will need to grapple with the ethics of opting in or out. He connects this to his own uncertainty about whether he'll personally benefit, acknowledging that at 53 (biological age 39) it may not fully apply to his lifespan, so his work is for future generations.

Young points out that neurodegenerative diseases are the last remaining frontier among the four major age-related disease categories, where we still 'don't know what we don't know.' He contrasts the past, where a group of scientists would take 30 years to target one disease, with Verge Genomics' approach that leverages AI and a vast brain tissue bank to run hundreds of programs simultaneously. This is enabled by computing power and artificial intelligence, which he believes will solve these problems within the next 5-15 years. He places this in the context of his broader optimism: heart disease is half-fought, cancer is being won through early detection, and metabolic disease is addressable with GLP-1 drugs and lifestyle. Neurodegeneration is the final boss, and AI is the weapon.

Young expresses excitement about a company he can only partly name (he says 'biolink' in a non-confidential aside) that is working on a micro-needling technology for continuous monitoring of seven different biomarkers with one device. He predicts this will reach the market next year, pending regulatory approval. He envisions a future where individuals can cherry-pick biomarkers—especially hormonal panels important for female health—and apply one patch-like device for real-time feedback. The device would replace episodic lab draws with continuous data, transforming how people manage their health. He frames this within his larger philosophy: the feedback loop of health data will shorten from months to seconds, enabling rapid lifestyle adjustments.

Young uses the metformin trial to highlight affordability in longevity science. He explains that metformin, a generic drug produced for over 60 years with a well-known safety profile, is so cheap that the placebo pill—a substance with zero active ingredient—is twice as expensive to produce for the trial. This, he argues, demonstrates that powerful longevity interventions don't need to be costly biotech breakthroughs; they can be repurposed generics priced for global access. He frames this as part of his mission to make longevity accessible to one billion people, not just a wealthy elite. He repeatedly reminds that this is research, not medical advice, but the irony drives home his point about democratizing healthspan.